摘要
采用立体定向放射治疗(SBRT)技术治疗早期不可手术的肺癌患者,其安全性及有效性已被证实,但随着SBRT研究的持续推进,对早期中央型和超中央型肺癌的放射治疗更加精准,且该类患者目前使用SBRT安全性存在争议,SBRT治疗分割剂量及次数尚无共识。基于现有循证医学证据,针对中央型和超中央型早期肺癌使用SBRT治疗现状及研究进展及安全性进行综述。
The safety and effectiveness of adopting stereotactic body radiotherapy(SBRT)had been proved in treating early inoperable lung cancer.With the continuous development of SBRT research in recent years,the treatment of that had been more accurate for the central and ultra-central type of lung cancer,while the safety of that still existed controversy when this type of patients used it,and there were still no consensus on the segmentation dose and frequency of SBRT.Based on the existing evidence of evidence-based medicine,this paper mainly reviewed the current status,research progress and safety of using SBRT in the treatment of central and ultra-central type of early stage lung cancer.
作者
刘彦立
饶乐
曲宝林
解传滨
刘芳
LIU Yan-li;RAO Le;QU Bao-lin(Department of Radiotherapy,The First Medical Center of Chinese PLA General Hospital,Beijing 100853,China;不详)
出处
《中国医学装备》
2023年第8期172-177,共6页
China Medical Equipment
基金
国家重点研发计划(2022YFC2409503)“基于临床放射治疗设备和新技术测试方法评价研究”。
关键词
早期肺癌
立体定向放射治疗(SBRT)
中央型肺癌
超中央型肺癌
Early stage flung cancer
Stereotactic body radiotherapy(SBRT)
Central type of lung cancer
Ultracentral type of lung cancer
